FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir
The FDA has accepted the New Drug Application (NDA) for IDVYNSO, which includes doravirine and islatravir.
Published: July 28, 2026
Updated: July 28, 2026
Author: Humanexa Intelligence
Therapeutic area: Infectious Disease / HIV
Company: Merck
Asset: IDVYNSO
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Merck
Asset
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's acceptance of the NDA for IDVYNSO represents a significant step in the regulatory process for a new combination therapy in the HIV treatment landscape. This could enhance MSD's competitive positioning and necessitate strategic adjustments for existing products in the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for FDA review and any upcoming announcements regarding approval status.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.